Company Performance Metrics
- Jennifer Buell: President and CEOPast Role: Agenus, President & Chief Operating Officer
- Terese Hammond: Head of Inflammatory and Pulmonary Diseases
MiNK Therapeutics is a clinical-stage biopharmaceutical company engaged in the development of allogeneic invariant natural killer T (iNKT) cell therapies. The company's pipeline includes both native and engineered iNKT programs, designed for scalable and reproducible manufacturing to enable off-the-shelf delivery. MiNK's lead product
candidate, agenT-797, is an allogeneic, native iNKT cell therapy being evaluated in clinical trials for its potential in treating solid tumors and immune-mediated diseases. Additionally, the company is developing engineered iNKT programs, such as MiNK-413 and MiNK-215, targeting specific antigens associated with cancer. MiNK's approach aims to harness the properties of iNKT cells to address unmet medical needs in oncology and immunology.
